Jae Hong Seo
Korea University · Medicine
About the Lab
Professor Jae Hong Seo's research lab specializes in translational cancer biology and medicinal chemistry, with a focus on understanding the tumor microenvironment, cancer stem cells (CSCs), and the development of repurposed drugs for aggressive cancers such as triple-negative breast cancer (TNBC), pancreatic, and biliary tract carcinomas. The lab investigates immunological markers, metastasis mechanisms, and the therapeutic potential of FDA-approved or existing drugs—like salinomycin, flubendazole, and 5-FU—against CSCs and tumor progression. Additionally, the lab contributes to synthetic organic chemistry, particularly in the stereoselective synthesis of complex natural products such as communesins, which serve as chemical probes and potential anticancer leads. Their work bridges molecular oncology, drug repositioning, and total synthesis to identify novel therapeutic strategies for treatment-resistant cancers.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15BACKGROUND: The balance in the immune system between immune surveillance against non-self-antigens and tolerance of self-antigens is known to be associated with the prognosis of breast cancer patients. However, immunologic signals in tumor microenvironment according to biological characteristics of cancer cells have not been clearly elucidated. CD4(+) T cells, CD8(+) T cells, and forkhead box P3-positive (Foxp3) regulatory T cells (Tregs) are the main keys for immune surveillance and tolerance,
In order to evaluate the role of BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer, 97 patients with sporadic breast cancer were analyzed for mutations in the BRCA1 and BRCA2 coding regions, by using a combination of fluorescent-conformation sensitive gel electrophoresis (F-CSGE) and direct sequencing. Fifty-five distinct sequence variants were detected, which included three pathogenic truncating mutations, 15 missense mutations, 16 polymorphisms, and 21 intronic
Some suggestive but not entirely consistent nor conclusive evidence was found on the association between the history of preeclampsia or PIH with the subsequent risk of breast cancer.
Despite recent advances, there remains a significant unmet need for the development of new targeted therapies for triple-negative breast cancer (TNBC). Although the heat shock protein HSP90 is a promising target, previous inhibitors have had issues during development including undesirable induction of the heat shock response (HSR) and off-target effects leading to toxicity. SL-145 is a novel, rationally-designed C-terminal HSP90 inhibitor that induces apoptosis in TNBC cells via the suppression
Research Areas
Dive deeper into Jae Hong Seo's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.